Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354831 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT04354831: Completed Phase 2 study, sponsored by Medical College of Wisconsin.
NCT04354831 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 131 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04354831, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Primary Outcome
Overall mortality during hospitalization for COVID-19. All patients were followed for the duration of their hospitalization, sometimes exceeding 60 days, through study completion.
Interventions
- BIOLOGICAL anti-SARS-CoV-2 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2021-02-10 |
| Phase | Phase 2 |
What the finished NCT04354831 record still lists
NCT04354831 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which anti-SARS-CoV-2 convalescent plasma is the first listed.
NCT04354831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04354831 about?
NCT04354831 is a clinical study titled "Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients". This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
What is the current status of trial NCT04354831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2020-05-11. Estimated completion is 2021-02-10.
What interventions are being tested in trial NCT04354831?
The interventions under investigation include: anti-SARS-CoV-2 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04354831?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04354831's enrollment target sits among peer trials
131 541st of 2000 higher than 1,458 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI